Pharma Reviews: Cut In Interconnect Usage Charges To Impact EBITDA Levels Of Incumbents By 4-5%

India Ratings estimates the impact of the cut on the standalone leverage .... Has anything fundamentally changed for Indian pharma companies?
Read more: Cut In Interconnect Usage Charges To Impact EBITDA Levels Of Incumbents By 4-5%